Literature DB >> 6134138

Fetal survival after prednisone suppression of maternal lupus-anticoagulant.

W F Lubbe, W S Butler, S J Palmer, G C Liggins.   

Abstract

The presence of the lupus anticoagulant was diagnosed in six pregnant women because they had prolonged activated partial thromboplastin and kaolin clotting times which could not be corrected by dilution of test samples with normal plasma. All previous pregnancies (14) had ended in intrauterine death in the five multigravidas. Three women had had thrombotic episodes during pregnancy. The diagnosis of SLE was established in four. Antinuclear antibody was identifiable in all 6. All were treated with prednisone 40-60 mg/day and aspirin 75 mg/day. Suppression of the lupus anticoagulant activity was achieved in five patients, all of whom gave birth to live infants. In the sixth patient suppression of the anticoagulant activity was demonstrated between pregnancies; a further pregnancy in this patient was lost before she had received sufficient prednisone to suppress the anticoagulant. Since treatment with prednisone and aspirin can lead to successful pregnancies, it is important to screen all women with SLE, thrombotic episodes, recurrent intrauterine deaths, or a biologically false-positive VDRL for the presence of the lupus anticoagulant.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6134138     DOI: 10.1016/s0140-6736(83)92141-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  48 in total

1.  How to treat women with antiphospholipid antibodies in pregnancy?

Authors:  R H Derksen; P G De Groot; H K Nieuwenhuis; G C Christiaens
Journal:  Ann Rheum Dis       Date:  2001-01       Impact factor: 19.103

2.  Antiphospholipid antibodies: which and when?

Authors:  R Cervera; J Font; M A Khamashta; G R Hughes
Journal:  Postgrad Med J       Date:  1990-11       Impact factor: 2.401

3.  Management of the antiphospholipid syndrome.

Authors:  M A Khamashta; T Wallington
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

4.  Methods for detecting lupus anticoagulants and their relation to thrombosis and miscarriage in patients with systemic lupus erythematosus.

Authors:  D Ferro; M Saliola; C Quintarelli; G Valesini; S Basili; A M Grandilli; M S Bonavita; F Violi
Journal:  J Clin Pathol       Date:  1992-04       Impact factor: 3.411

5.  Immunoadsorbent plasmapheresis for a patient with antiphospholipid syndrome during pregnancy.

Authors:  S Kobayashi; N Tamura; H Tsuda; C Mokuno; H Hashimoto; S Hirose
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

6.  Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus.

Authors:  H J Out; M van Vliet; P G de Groot; R H Derksen
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

Review 7.  Neonatal effects of maternal antiphospholipid syndrome.

Authors:  Angela Tincani; Chiara Biasini Rebaioli; Laura Andreoli; Andrea Lojacono; Mario Motta
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

8.  When conventional treatment fails: the role of intravenous immunoglobulin in recurrent pregnancy loss secondary to antiphospholipid syndrome.

Authors:  Jacklyn Chay; Karin Lust; Paul Kubler; Leonie Callaway
Journal:  Obstet Med       Date:  2013-05-03

9.  The lupus anticoagulant, pulmonary thromboembolism, and fatal pulmonary hypertension.

Authors:  N E Anderson; M R Ali
Journal:  Ann Rheum Dis       Date:  1984-10       Impact factor: 19.103

Review 10.  Current issues in thrombosis prevention with antiplatelet drugs.

Authors:  G de Gaetano; C Cerletti; E Dejana; J Vermylen
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.